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The tincture of Operculina alata, popularly known as “tincture of jalapa”, is used in Northeast Brazil to 
treat constipation and encephalic vascular accident, but it has not yet been adequately tested for safety 
and efficacy. The aim of this study was to evaluate the toxicology and safety of the tincture of O. alata in 
patients with functional constipation. This was a double-blind, randomized, placebo-controlled clinical 
trial. The study consisted of three phases: pre-treatment, treatment and post-treatment, each phase 
with duration of seven days. Arterial pressure, heart rate, body weight, adverse events, hematological, 
metabolic, liver and kidney functions were monitored. Forty patients were randomized to receive 
tincture of O. alata and 43 patients to receive placebo. There were statistical differences in the clinical 
aspects between groups, but these changes were not considered clinically significant. Adverse events 
were considered not serious and of mild intensity, especially dizziness, headache, abdominal pain and 
nausea. This clinical trial confirmed the safety of the tincture of O. alata in the pharmaceutical form 
and dosage tested, allowing the product to be safely used in a larger population for the assessment of 
its clinical efficacy.
Uniterms: Operculina alata/pharmacognosy. Operculina alata/tincture/toxicological evaluation. 
Operculina alata/tincture/safety. Tincture of Jalapa see Operculina alata/tincture.
A tintura de Operculina alata, popularmente conhecida como “tintura de jalapa”, é usada no Nordeste 
do Brasil para tratar constipação intestinal e acidente vascular encefálico, mas sua eficácia e segurança 
ainda não foram confirmadas. O objetivo deste estudo foi avaliar a toxicologia e segurança da tintura 
de O. alata em pacientes com constipação intestinal funcional. Este foi um ensaio clínico duplo-cego, 
randomizado e controlado por placebo. O estudo consistiu de três fases: pré-tratamento, tratamento e 
pós-tratamento, cada fase com duração de sete dias. Foram monitorizados a pressão arterial, frequência 
cardíaca, peso corporal, eventos adversos e funções hematológica, metabólica, hepática e renal. Quarenta 
pacientes foram randomizados para receber tintura de O. alata e 43 pacientes para receber placebo. 
Houve diferenças estatísticas nos aspectos clínicos entre os grupos, contudo, estas mudanças não foram 
consideradas clinicamente significativas. Eventos adversos foram considerados não sérios e de leve 
intensidade, especialmente, cefaléia, tontura, dor abdominal e náusea. Este ensaio clínico confirmou a 
segurança da tintura de O. alata na forma farmacêutica e dosagem testada, permitindo que o produto 
seja testado em população maior para determinar sua eficácia clínica.
Unitermos: Operculina alata/farmacognosia. Operculina alata/tintura/avaliação toxicológica. Operculina 
alata/tintura/segurança. Tintura de Jalapa see Operculina alata/tintura.
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INTRODUCTION
The tincture of O. alata is an extract derived from 
Operculina alata Urban, a plant that belongs to the Con-
volvulaceae family. It is found in the tropical and subtropi-
cal regions between the Antilles and Brazil and temperate 
regions of the Mexican Andes, and is known as jalapa. 
The tincture has been used as a laxative in popular medi-
cine (Matos, 2000; Gomes et al., 2009). One of the most 
interesting characteristics of this family is the presence of 
secretory cells that secrete glycosidic resins in foliar tissue 
and especially in roots (Gomes et al., 2009). In fact, plant 
substances are potential sources of clinically important 
drugs (Moraes et al., 2008).
A preclinical study has demonstrated laxative ac-
tivity in the hydroalcoholic extract of the O. alata tuber 
in mice using the intestinal motility test (Michelin, Sal-
gado, 2004). A chronic toxicity study determined that the 
hydroalcoholic extract is safe in adult Wistar rats when 
administered orally (13 weeks) (Gonçalves et al., 2007). 
The tincture of O. alata is characterized as a stimulant or 
irritant laxative.
Constipation is a very common disease, affecting 2 
to 27% of the population (Garrigues et al., 2004; Lembo, 
Camilleri, 2003; Pare et al., 2001). The definition of func-
tional constipation in adults, according to Rome III criteria, 
a system developed to classify functional gastrointestinal 
disorders, is as follows: less than three bowel movements 
per week, on average, during the last three months, and/
or with excessive need for straining, hard stool, low stool 
weight or sensation of incomplete evacuation in more than 
a quarter of the evacuations (Longstreth et al., 2006).
Several classes of medicines are used for the treat-
ment of constipation. However, it has been observed in 
the last decades a constant increase of the use of herbal 
medicines, which has been encouraging scientific studies 
for the discovery of new substances with therapeutic ac-
tion and for the confirmation of the efficacy and safety of 
medicines derived from plants (Hansen et al., 2010; Ma 
et al., 2010; Moraes et al., 2012). The safe use of herbal 
drugs requires knowledge of their chemical properties and 
possible adverse effects (Fejzic et al., 2010; Teschke et 
al., 2010). Plant materials are used throughout the world 
as home remedies or raw materials for the pharmaceuti-
cal industry and represent a substantial proportion of the 
global drug market (Bosnic et al., 2007). With the continu-
ous increase in the use of herbal medicines worldwide, 
the safety and quality of herbal medicines have become a 
major concern (Kamil et al., 2010).
Therefore, the aim of the present study was to inves-
tigate the toxicology and safety of the tincture of O. alata 
in the treatment of patients with functional constipation. It 
has a low cost and has been widely used indiscriminately 
to treat constipation, but its safety in humans has not yet 
been proved through clinical trials.
MATERIAL AND METHODS
Patients
This study was conducted in accordance with the 
Declaration of Helsinki, and the protocol was approved by 
the Ethics Committee of the Federal University of Ceará, 
in Fortaleza, Brazil, and registered under No.160/08 
(33/08). All patients gave their written informed consent 
and were free to withdraw from the trial at any time.
The patients were recruited from the Clinical Phar-
macology Unit and submitted to a clinical evaluation to 
confirm the diagnosis of functional constipation, according 
to the Rome III criteria (Longstreth et al., 2006). The criteria 
for inclusion in the study were as follows: male or female, 
aged 18 years and older, having a body mass index (BMI) 
between 19 and 30, and confirmed diagnosis of functional 
constipation. Exclusion criteria included hypersensitivity to 
the study drug, addiction to drugs, constipation associated 
with drug treatment, use of experimental drugs in the previ-
ous 6 months, laboratory tests showing clinical abnormali-
ties, untreated illnesses, pregnancy and lactation.
The patients maintained their routine activities and 
diet. They were instructed to report any adverse events, 
time of occurrence and use of concomitant medication. 
Female patients of child-bearing potential were included 
after confirmation of a negative pregnancy test (β-subunit 
of human chorionic gonadotropin; HCG), and were recom-
mended to use highly effective methods of birth control 
contraceptives during the study such as oral contraceptive 
and condom, intra-uterine device (IUD) and condom or 
diaphragm with spermicide and condom.
Study design
The randomized, double-blind, placebo controlled 
study, consisted of three phases – pre-treatment, treatment 
and post-treatment – with each phase lasting 7 days. Dur-
ing pre-treatment, the patients signed an informed consent 
form and had their diagnosis of functional constipation 
confirmed. The treatment phase consisted of randomiza-
tion and administration of a single daily dose of 15.0 mL 
of the tincture of O. alata or placebo, followed by drink-
ing 200.0 mL of water. The post-treatment consisted of 
an evaluation of the patient following drug or placebo 
administration.
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The tincture of O. alata (Tincture of Jalapa Sobral®) 
was produced by the Sobral Pharmaceutical Laboratory, 
located in Piaui, Brazil. Voucher specimens (No. 58836) 
were deposited in the Herbarium of the Agricultural Re-
search Company of Pernambuco. The tincture contains 
O. alata tuber as a powder in a 50% hydroalcoholic ve-
hicle. The placebo was the hydroalcoholic vehicle. Each 
milliliter of the tincture consisted of 200 mg of O. alata 
root powder, containing 1.5 to 1.9% resin glycosides, 
the pharmacologically active substances. The dose of 
15.0 mL, used in this study, contained between 45.0 and 
57.0 mg of resin.
The resin is obtained by hydroalcoholic extraction 
and has organic and inorganic constituents, which can be 
divided into two main parts: one CHCl3-soluble (“jalapin” 
or nonpolar fraction) and MeOH-soluble (“convolvulin” or 
polar fraction). The action of jalapa is due to the high resin 
content present in the tuber, which contains glycosides 
that, in the presence of bile, are hydrolyzed into a sugar and 
aglycone, releasing the corresponding free fatty acid. Free 
fatty acids irritate the intestinal mucosa, increase peristal-
sis, and facilitate evacuation (Pereda-Miranda et al., 2006; 
Teske, Trentini, 1997). Separation by reverse phase HPLC 
shows that the active constituents are a mixture of resin 
glycosides (Pereda-Miranda, Bah, 2003).
Safety and tolerability
Patients were asked to record any adverse events 
in a diary on a daily basis. Adverse events were mapped 
to reference terms and body systems and coded accord-
ing to the Adverse Reaction Terminology Dictionary of 
the World Health Organization - WHO (WHO, 2010). In 
addition, the occurrence of any adverse event identified 
through questioning of the investigator was recorded. All 
adverse events were assessed and recorded in detail by the 
investigator and reported in accordance with regulatory 
definitions, in terms of severity, duration and outcome, 
etiology and relationship to the study drug.
Laboratory tests were performed in the pre-treatment 
and post-treatment phases, including hemoglobin, red 
blood cell count, hematocrit, platelets, leukocytes, lym-
phocytes, basophils, eosinophils, monocytes and neutro-
phils and serum levels of albumin, alkaline phosphatase, 
total, direct and indirect bilirubin, creatinine, g-glutamyl 
transferase (GGT), glucose, electrolytes (K+, Na+), glu-
tamic oxaloacetic transaminase (aspartate aminotransfer-
ase – AST) and glutamic pyruvic transaminase (alanine 
aminotransferase – ALT) as well the β-subunit of HCG in 
female patients of child-bearing potential.
Analyses were performed by a local accredited labo-
ratory at each investigator site. When values for a given 
sample were outside the normal range, the analysis was 
repeated to confirm the findings. Abnormal values were 
recorded by the investigator on the case report form, and 
an assessment of its possible etiology was performed.
Systolic (SAP), diastolic (DAP) and mean arterial 
pressure (MAP), measured non-invasively with a sphyg-
momanometer, and heart rate (HR) were recorded in the 
pre-treatment, treatment for five days (T1, T2, T3, T4 
and T5) and post-treatment, after 30 minutes of rest in a 
sitting position. Body weight (BW) was obtained in the 
pre-treatment and post-treatment phases.
Statistical analysis
The quantitative variables were initially analyzed 
by the Kolmogorov-Smirnov Test to verify the normality 
of distribution. For descriptive statistics, the mean and 
standard deviation for parametric data or median and 
interquartile range (nonparametric data) were calculated. 
Comparisons between groups (placebo versus jalapa) in 
each phase of the study (pre-treatment, treatment and post-
treatment) were made using the t test for unpaired variables 
(parametric data) or Mann-Whitney test (nonparametric 
variables). Comparisons between the pre-treatment and 
post-treatment phases in the same group were made using 
the t test for parametric data or Wilcoxon test for nonpara-
metric variables.
Comparisons between the three phases (pre-treat-
ment, treatment and post-treatment) in the same group 
were carried out by analysis of variance (ANOVA) for 
repeated measurements and complemented by Tukey’s 
multiple comparison test (parametric data) or by the Fried-
man test associated with Dunn’s multiple comparison test 
(nonparametric variables). Qualitative variables were 
expressed as absolute and relative frequency, analyzed by 
Fisher’s exact test. A 5% probability of a type I (α) error 
(significance level) was established, and a 2-tailed P<0.05 
was accepted as significant. The statistical software Graph-
Pad Prism® version 5.00 was used for data processing and 
preparations of the graphs.
RESULTS
Of the 155 patients initially evaluated, only 83 met 
the inclusion criteria, where all of them were female. Forty 
patients were randomized to receive tincture of O. alata 
and 43 to receive placebo. Two patients in the jalapa group 
and five in the placebo group were lost to follow-up and so 
were withdrawn from the trial due to deviation from the 
experimental protocol.
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Patient pre-treatment characteristics were similar 
for the groups (expressed as mean ± standard deviation): 
placebo group: 37.45±9.61 years and BMI of 25.03±2.99; 
jalapa group: 33.21±11.51 years and BMI of 24.21±3.01.
DAP, MAP and BW did not show statistically signifi-
cant differences (P>0.05) in the placebo and jalapa groups 
during the study. BW was expressed as mean ± standard de-
viation: pre-treatment, placebo group: 60.80±8.30 kg; jalapa 
group: 60.30±8.92 kg and post-treatment, placebo group: 
61.06±8.27 kg; jalapa group: 60.50±8.94 kg (Figure 1).
It was found that in T1, SAP observed in the jalapa 
group was significantly higher than in the placebo group 
(*P=0.04). In the placebo group, SAP measured at T3 was 
significantly lower (+P<0.05) than that measured in the 
pre-treatment and post-treatment. In the post-treatment, 
HR in the jalapa group was significantly higher than in 
the placebo group (*P=0.03). In the placebo group, HR in 
the pre-treatment was significantly lower than at T1 and 
T3 (++P<0.01) and T2 and T4 (+++P<0.001), and HR of the 
placebo group in the post-treatment was also found to be 
significantly lower compared to T2 and T4 (#P<0.05). De-
spite the differences, the systolic arterial pressure and the 
heart rate remained within normal parameters (Figure 1).
The hematological, metabolic and liver and kidney 
function parameters of the placebo and jalapa groups were 
evaluated through laboratory tests performed during the 
pre-treatment and post-treatment. Statistically significant 
differences were found, although the values were within 
the normal ranges, showing no clinical relevance (Tables 
I and II).
Adverse events were reported by 13 patients (34%) 
in the jalapa group and 12 patients (31%) in the placebo 
group (Table III). The most common adverse events were 
FIGURE 1 - SAP, DAP, MAP and HR of the placebo and jalapa groups in the pre-treatment, treatment and post-treatment. A - 
*P=0.04: In T1 SAP of jalapa group > placebo group. +P<0.05: In T3, PAS of placebo group < pre-treatment and post-treatment. 
B and C - No statistically significant differences (P>0.05) were found between the two groups and evaluated times. D - *P=0.03: 
HR of the post-treatment in the jalapa group > placebo group. HR of the pre-treatment in the placebo group < T1, T3 (++P<0.01) 
and T2, T4 (+++P<0.001); #P<0.05: HR of the post-treatment in the placebo group < T2 and T4.
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TABLE I - Hematological test results of the placebo and jalapa groups in the pre-treatment and post-treatment, expressed as mean 
± standard deviation or median and interquartile range
Parameter
Pre-treatment Post-treatment Reference 
valuesPlacebo Jalapa P value1 Placebo Jalapa P value1
Hemoglobin 12.90±0.71 12.85±0.74 0.72 12.74±0.68 12.81±0.74 0.53 11.5–16.4 g/dL
Red blood cells 4.42±0.35 4.40±0.25 0.70 4.34±0.31+ 4.38±0.31 0.51 3.9–5.8 106/mm3
Hematocrit 38.72±1.94 38.43±1.85 0.51 38.27±1.83+ 38.32±2.12 0.90 36.0%–47%
Platelets 274.03±58.75 255.71±47.00 0.13 266.68±57.97 262.76±48.10 0.74 150–450 103/mm3
Leukocytes 6.83±1.46 6.92±1.78 0.81 6.47±1.40 6.78±1.78 0.39 3.6–11 103/mm3
Lymphocytes 33.66±7.13 32.87±7.78 0.64 34.05±8.25 33.45±7.86 0.74 20–50 %/mm3
Basophils 0.00 (0.00–1.00) 0.00 (0.00–1.00) 0.90 0.50 (0.00–1.00) 1.00 (0.00–1.00) 0.83 0–3 %/mm3
Eosinophils 2.00 (1.75–3.00) 3.00 (2.00–5.00) 0.07 3.00 (2.00–4.00)++ 3.00 (2.00–4.00) 0.78 0–6 %/mm3
Monocytes 8.62±1.89 8.91±2.07 0.54 8.74±2.12 8.77±2.78 0.74 2–10%/mm3
Neutrophils 55.18±8.22 53.58±8.44 0.40 54.00±7.93 54.37±9.02 0.85 45–70/mm3
1Intergroup significance. +P<0.05 and ++P=0.01: in relation to pre-treatment in the same group.
TABLE II – Metabolic and liver and kidney function laboratory test results of the placebo and jalapa groups in the pre-treatment 
and post-treatment, expressed as mean ± standard deviation
Parameter
Pre-treatment Post-treatment Reference 
valuesPlacebo Jalapa P value1 Placebo Jalapa P value1
Albumin 4.45±0.19 4.44±0.25 0.97 4.42±0.20 4.43±0.23 0.82 3.4–4.8 g/dL
Alkaline phosphatase 66.57±18.12 59.65±18.15 0.10 60.46±18.54 58.05±16.82 0.55 35–104 U/L
Bilirubin total 0.61±0.21 0.57±0.20 0.45 0.59±0.19 0.49±0.19+ 0.02* ≤ 1.1 mg/dL
Bilirubin direct 0.14±0.06 0.14±0.06 0.83 0.15±0.06 0.12±0.06+ 0.23 ≤ 0.3 mg/dL
Bilirubin indirect 0.46±0.16 0.43±0.15 0.36 0.44±0.15 0.37±0.14+ 0.03* ≤ 0.7 mg/dL
Creatinine 0.69±0.13 0.66±0.11 0.22 0.70±0.13 0.66±0.11 0.13 0.6–1.2 mg/dL
GGT 22.75±14.60 15.88±7.16 0.01* 22.51±15.90 16.79±8.60 0.05 5–36 U/L
Glucose 86.87±7.85 84.97±7.38 0.21 88.37±8.43 84.18±5.36 0.02* 70–99 mg/dL
K+ 4.22±0.34 4.09±0.31 0.09 4.12±0.30 4.14±0.28 0.78 3.5–5.5 mEq/L
Na+ 139.34±1.79 139.47±1.89 0.75 139.53±2.31 139.53±1.35 1.00 135–145 mEq/L
AST 19.89±4.48 17.89±2.94 0.02* 19.13±4.71 18.93±6.51 0.87 ≤ 32 U/L
ALT 18.52±6.66 15.26±5.13 0.01* 16.95±9.98 16.18±12.53 0.76 ≤ 31 U/L
1Intergroup significance. *P<0.05 and +P<0.05: in relation to pre-treatment in the same group.
TABLE III - Adverse events reported by the patients in the jalapa and placebo groups
Event Placebo group Jalapa group Significance
Dizziness 5 (13.15%) 8 (21.05%) P = 0.543
Headache 4 (10.52%) 4 (10.52%) P = 1.000
Abdominal pain 3 (7.89%) 4 (10.52%) P = 1.000
Nausea 4 (10.52%) 0 (0.00%) P = 0.115
Drowsiness 0 (0.00%) 2 (5.26%) P = 1.000
Epigastric pain 2 (5.26%) 0 (0.00%) P = 0.933
Heartburn 0 (0.00%) 2 (5.26%) P = 0.493
Asthenia 0 (0.00%) 2 (5.26%) P = 0.493
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dizziness, headache, abdominal pain and nausea. In the 
statistical analysis by Fisher’s exact test, there were no 
significant differences between the proportion of patients 
who had adverse events in the jalapa and the placebo 
groups, demonstrating the safety of using the tincture of 
O. alata. All adverse events were considered not serious, 
of mild intensity and attributed to the presence of alcohol 
in the formulation. No patient was withdrawn from the 
study due to adverse events.
DISCUSSION
The tincture of O. alata has been used indiscrimi-
nately in popular medicine through self-medication in 
the treatment of constipation and other diseases, such as 
bronchitis, asthma and cerebrovascular disease, with no 
confirmation of its safety and efficacy. This double-blind, 
randomized, placebo-controlled clinical trial is the first 
study to evaluate the toxicology and safety of tincture of O. 
alata in patients with functional constipation. The tincture 
of O. alata is classified as an irritant laxative or stimulant 
of the gastrointestinal tract. This study was conducted in 
patients with constipation because even a laxative dose 
could cause diarrhea in healthy subjects. The period of 
treatment was seven days, because an irritant laxative 
should not be recommended for chronic or prolonged use 
(Pasricha, 2005).
The most commonly used drugs belonging to this 
class of irritant or stimulant laxatives are anthraquinones, 
mainly represented by senna and diphenylmethane deriva-
tives, such as bisacodyl. Stimulant laxatives increase in-
testinal motility and secretions by stimulating the colonic 
myenteric plexus and altering fluid and electrolyte flow 
(Tack, Müller-Lissner, 2009).
Demographic data showed that all patients of the 
study were female with ages ranging from 21 to 47 years 
in both groups. The occurrence of only female patients is 
due to the high prevalence of women with constipation. 
This is justified by studies that report that constipation 
is more common in women (Pasricha, 2005; Klaschik et 
al., 2003). The prevalence may be three times higher in 
females than in males, mainly associated with cultural 
factors (Higgins, Johanson, 2004).
Tolerance to stimulant laxatives may occur mostly 
in patients with severe slow time colonic transit, in which 
other types of laxatives are ineffective, but tolerance is 
uncommon in the majority of users (Müller-Lissner et 
al., 2005). The intermittent use of stimulant laxatives 
seems to be well accepted by investigators, sponsors, 
ethical committees and regulatory authorities because they 
have been used as rescue therapy in many clinical trials 
with constipation and in irritable bowel syndrome (Tack, 
Müller-Lissner, 2009). Also, alternative medicines are 
increasingly popular due to the fact that the compounds 
are natural, well tolerated and lack side effects (Kalus et 
al., 2010).
The clinical examinations, physical evaluation and 
laboratory tests performed before and after the research did 
not show toxicity signs in the various organs and systems 
assessed. Systolic arterial pressure, heart rate, red blood 
cells, hematocrit, eosinophils, glucose, total bilirubin, di-
rect and indirect bilirubin showed statistically significant 
changes. Nevertheless, the results remained within normal 
limits and were not clinically significant.
The adverse events reported for the jalapa group and 
placebo group were all classified as non-serious and mild. 
The most common adverse events were dizziness, head-
ache, abdominal pain and nausea, not considered clinically 
significant and actually related to the alcohol concentration 
in the formulation of the phytotherapic medicine. Alcohol 
is a depressant of the central nervous system and can cause 
the observed effects depending on the dose ingested (Pas-
richa, 2005). These events did not result in any withdrawn 
from the trial. Abdominal pain, nausea and other disorders 
of the gastrointestinal tract can also be related to the resin 
present in the tincture of O. alata. The action of jalapa is 
due to the high resin content present in the tuber, a stimu-
lant of the intestinal mucosa, increasing peristalsis and 
facilitating evacuation (Tesk, Trentini, 1997). This action 
may have caused the abdominal pain and the other gastric 
disorders reported by the subjects of the study.
The observed adverse events have also been reported 
for other stimulant laxatives. In the assessment of the 
safety of bisacodyl and Smooth Move®, which contains 
senna (Cassia angustifolia Vahl), it was observed that 
most adverse events were gastrointestinal tract disorders 
(Kienzle-Horn et al., 2006; Bub et al., 2006).
In a preclinical study of acute and chronic toxicol-
ogy in Wistar rats, there were no toxic effects at the doses 
of hydroalcoholic extract of O. alata tested, which were 
25 times higher than the therapeutic dose recommended 
for the laxative effect. It did not modify the biochemical 
and hematological profiles of the animals after treatment, 
showing it to be a safe phytotherapeutic product (Gon-
çalves et al., 2007).
Tincture of O. alata has proved effective in acute 
treatment of functional constipation in humans through a 
randomized, double-blind, and placebo-controlled clinical 
trial. This phytotherapeutic medication showed a significant 
beneficial effect, representing an alternative for the acute 
treatment of functional constipation (Cunha et al., 2011).
There were difficulties in comparing the results 
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obtained with other studies due to the existence of only 
preclinical toxicology studies of the tincture of O. alata. 
It was not possible to determine the tolerance and de-
pendence of this phytotherapeutic medicine when used 
for extended periods, since it was only tested for acute 
treatment. Furthermore, we suggest a reassessment of the 
current formulation of the phytotherapeutic medicine to 
reduce the alcohol concentration and prevent potential 
adverse events related to alcohol.
CONCLUSIONS
This clinical trial confirmed the safety of the tincture 
of O. alata in the pharmaceutical form and dosage tested, 
allowing the product to be safely used in a larger popula-
tion. In addition, phytotherapeutic medicines can be of 
great economic, medicinal, and social importance, when 
produced with rigorous quality control and used properly 
by patients.
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